Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | KCNB1 | Q14721 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6647166 | 0.87 | KCNH2 (0.48) | L3MBTL1KCNH2KCNB1RAB9AHPGD | |
| SCHEMBL6647603 | 0.85 | CTNNB1 (0.48) | L3MBTL1KCNH2KCNB1RAB9AHPGD | |
| SCHEMBL6645079 | 0.85 | KMT2A (0.51) | L3MBTL1RAB9ANPC1SMN1; SMN2KDM4E | |
| SCHEMBL6649784 | 0.83 | NAMPT (0.53) | L3MBTL1KCNH2KCNB1RAB9ANPC1 | |
| SCHEMBL6831066 | 0.81 | KCNH2 (0.44) | L3MBTL1KCNH2KCNB1RAB9AHPGD | |
| SCHEMBL6644991 | 0.81 | CTNNB1 (0.41) | L3MBTL1KCNH2KCNB1RAB9AHPGD | |
| SCHEMBL6643783 | 0.80 | MAPT (0.46) | KCNH2KCNB1RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL6490174 | 0.80 | GCGR (0.54) | CA1CA2CA5ACA7CA5B | |
| SCHEMBL6643766 | 0.79 | CTNNB1 (0.43) | L3MBTL1KCNH2KCNB1RAB9AHPGD | |
| SCHEMBL6643855 | 0.79 | ALDH1A1 (0.48) | CA1CA2CA5ACA7CA5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040133008-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| WO-2004039795-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133008-A1 | Amide compounds | APOB, APOL1, LDLR | CA1 3588/4885CA2 2972/4885CA5A 3477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.